AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9284731
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.036 U/kg.day
Trial: 29537647
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE, 0.625 mg/day) + medroxyprogesterone acetate (MPA, 2.5 mg/day)
Trial: 11360606
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 0.75 mg taken twice with 12 hours apart
Trial: 11360606
Drug: Mifepristone (Mife-)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (Mife-) single dose of 10 mg and placebo 12 hours after
Trial: 7484025
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5 times the ED50 doses of mivacurium and pancuronium (cMP)
Trial: 7484025
Drug: cMP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMP administered to the same IV-line
Trial: 7484025
Drug: cMP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMP administered to two separate IV-lines in opposite hands
Trial: 1322075
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg twice daily for 10 days)
Trial: 1322075
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily for 10 days)
Trial: 6095356
Drug: Imipramine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (after treatment)
Trial: 31663443
Drug: ADC gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC gel
Trial: 24578470
Drug: Control (glucose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (glucose-based dialysis solution)
Trial: 17885238
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (retreatment)
Trial: 17885238
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (retreatment) for small aneurysms (< or =10 mm) with small necks (< or =4 mm)
Trial: 17885238
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with residual aneurysm after the first treatment
Trial: 15070873
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.1 mg triptorelin)
Trial: 11576319
Drug: Anti-hypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive treatment for 3 months with a calcium-antagonist in randomized combination with either an ACE inhibitor or a beta-blocker
Trial: 9592630
Drug: Other antidepressants
RxNorm normalized name: Other antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antidepressants or lithium
Trial: 8169616
Drug: High-dose nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nicardipine (0.15 mg/kg/hr)
Trial: 8169616
Drug: Low-dose nicardipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nicardipine (0.075 mg/kg/hr)
Trial: 8169616
Drug: High-dose nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nicardipine
Trial: 8169616
Drug: Low-dose nicardipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nicardipine
Trial: 30115326
Drug: C. etunicatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. etunicatum + G. albida
Trial: 11039202
Drug: IFN a-2
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN a-2 monotherapy (10 million I.U. in 50 ml physiological saline)
Trial: 11039202
Drug: IFN a-2
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN a-2 + Farmarubicin (FRC) combination (50 mg in 50 ml physiological saline)
Trial: 11039202
Drug: IFN a-2
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN a-2 monotherapy and IFN a-2 + FRC combination (Group I + II)
Trial: 11039202
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control Group III)
Trial: 31523892
Drug: Neladenoson bialanate
RxNorm normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neladenoson bialanate (5, 10, 20, 30, and 40 mg)
Trial: 18044259
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ascorbic acid
Trial: 11875333
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.025 mg/day) and norethisterone acetate (0.125 mg/day)
Trial: 10435260
Drug: Standard program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard program (longer inpatient treatment)
Trial: 10435260
Drug: Abbreviated Inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated Inpatient program (shorter inpatient treatment)
Trial: 7787134
Drug: Furosemide controlled
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide controlled release formulation (FR) with breakfast
Trial: 7787134
Drug: Furosemide controlled
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide controlled release formulation (LR) with breakfast
Trial: 7787134
Drug: Furosemide controlled
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide controlled release formulation (FR) fasting
Trial: 7787134
Drug: Furosemide controlled
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide controlled release formulation (LR) fasting
Trial: 2186825
Drug: Banked donor
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banked donor milk or preterm formula as sole diet or supplement to mother's expressed breast milk in trial A
Trial: 203635
Drug: BRL 5907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 5907 (5 mg per day for three days)
Trial: 28580708
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXT) 24 IU
Trial: 21300350
Drug: Fluvastatin (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (10mg daily for 30 days)
Trial: 16721398
Drug: Low-fat cheese
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat cheese enriched with 2 g of plant stanols per day
Trial: 15201248
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral dose of oestradiol
Trial: 15201248
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol orally/day for 12 weeks
Trial: 11167171
Drug: isobaric mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isobaric mepivacaine 20 mg/ml
Trial: 11167171
Drug: isobaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isobaric lidocaine 20 mg/ml
Trial: 9315790
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 200 microg (1 puff bid)
Trial: 9315790
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 400 microg (2 puffs bid)
Trial: 9315790
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 800 microg (4 puffs bid)
Trial: 9315790
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 1600 microg (8 puffs bid)
Trial: 8361220
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, maintenance therapy for 120 weeks (GBTLI-80)
Trial: 8361220
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, continuous maintenance for 2 years (GBTLI-82)
Trial: 8361220
Drug: No cranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cranial radiation, CNS protection with triple intrathecal therapy, consolidation therapy with high dose ARA-C for high risk patients (GBTLI-85)
Trial: 2940953
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (200 mg by spinhaler) + Atropine sulfate (2.0 mg by nebulizer)
Trial: 2940953
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (200 mg) + Ipratropium bromide (200 micrograms)
Trial: 2940953
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (200 mg)
Trial: 2940953
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate (2.0 mg)
Trial: 27436469
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (doxycycline and ceftriaxone)
Trial: 27436469
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (benzathine penicillin G)
Trial: 25193534
Drug: Low-dose UPA-CVR
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UPA-CVR (1500 μg/day)
Trial: 25193534
Drug: High-dose UPA-CVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UPA-CVR (2500 μg/day)
Trial: 25193534
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 1.5 mg orally
Trial: 22994618
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical therapy once a month for 6 months, along with educational support, counselling and audiovisual materials
Trial: 18396455
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) 200 mg/day for 8 weeks
Trial: 17338717
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in patients with CKD
Trial: 17338717
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in patients without CKD
Trial: 15284015
Drug: 10.5 mg
RxNorm normalized name: pectin 10.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 mg total dose (three vials of SALon)
Trial: 15284015
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg total dose (five vials of SALon)
Trial: 11876441
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg capsules
Trial: 11876441
Drug: Tramal 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramal 50 mg capsules (control)
Trial: 2893867
Drug: biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biosynthetic human growth hormone (BSHGH) 0.1 mg/kg daily for the first 7 postoperative days
Trial: 20921837
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 0.5% (15 mg), morphine 0.4 mg, and fentanyl 15 μg
Trial: 20921837
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.4 mg and fentanyl 15 μg
Trial: 8928187
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human insulin infused at 40 mU/m2/min for 2 hr
Trial: 8928187
Drug: 10% xylitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% xylitol infused at 100 ml/hr for 2 hr (control)
Trial: 1824218
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g salt per day diet (Group I)
Trial: 1824218
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g salt per day diet (Group II)
Trial: 6787909
Drug: Glucose-insulin-potassium (G-I-K)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (G-I-K) infusion (300 gm of glucose, 50 units of insulin, and 80 mEq of KCl per liter at a rate of 1.5 ml/kg/hr for 48 hours)
Trial: 24335748
Drug: ED treatment
RxNorm normalized name: NOSEBLEED TREATMENT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED treatment after 12 weeks
Trial: 24335748
Drug: Non-drug, run-in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug, run-in period (4 weeks)
Trial: 22673926
Drug: Oseltamivir (Tamiflu®)
RxNorm normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir (Tamiflu®) 75 mg single dose
Trial: 22145462
Drug: Low Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Insulin Response Diet (LIR)
Trial: 10940701
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (radiotherapy with neoadjuvant cisplatin)
Trial: 8258615
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray (100 micrograms)
Trial: 3910429
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (G-II)
Trial: 3910429
Drug: Standard anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anaesthesia (G-I)
Trial: 29913001
Drug: Rituximab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (2 infusions of 375 mg/m2)
Trial: 29913001
Drug: Tacrolimus (along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (along with tapering alternate-day prednisolone for 12 months)
Trial: 24913242
Drug: Intraoperative 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative 1 mg morphine bolus (Group B)
Trial: 24913242
Drug: Intraoperative 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative 2 mg morphine bolus (Group C)
Trial: 24913242
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural morphine infusion of 0.2 mg/h with 0.1% levobupivacaine via PCEA (all groups)
Trial: 24913242
Drug: No intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intraoperative morphine loading (Group A)
Trial: 21300723
Drug: Skeletal anchorage
RxNorm normalized name: Spongia officinalis skeleton extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skeletal anchorage (Onplant or Orthosystem implant)
Trial: 10866044
Drug: Low glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glucosamine infusion (1.6 micromol x min(‐1) x kg(‐1))
Trial: 10866044
Drug: High glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glucosamine infusion (5 micromol x min(‐1) x kg(‐1))
Trial: 9174428
Drug: Goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively (Group B)
Trial: 9174428
Drug: Goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively and repeated on the day of endometrial resection (Group C)
Trial: 9174428
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group A, no preoperative preparation)
Trial: 17314338
Drug: Valacyclovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (500 mg twice daily)
Trial: 19493958
Drug: modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modafinil (300 mg)
Trial: 19493958
Drug: prazosin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin (3 mg)
Trial: 19493958
Drug: modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modafinil (300 mg) and prazosin (3 mg) together
Trial: 12815555
Drug: Oxymetholone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetholone (50 mg bid)
Trial: 12815555
Drug: Oxymetholone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetholone (50 mg tid)
Trial: 24570989
Drug: Machined neck
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined neck implants (group 1)
Trial: 24570989
Drug: Rough, grooved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough, grooved neck implants (group 2)
Trial: 12372132
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg Fexofenadine (FEX)
Trial: 12372132
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Desloratadine (DL)
Trial: 10535855
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CSA) to achieve whole blood trough levels of 120‐150 ng/ml
Trial: 2187169
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg b.i.d. IM from the day before operation to the 7th postoperative day, n = 60)
Trial: 2187169
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5000 IU t.i.d. SC from the operation to the 7th postoperative day, n = 70)
Trial: 31866211
Drug: Health for
RxNorm normalized name: Eye Health Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health for Hearts United intervention (3 treatment churches)
Trial: 19242485
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid and oral ibuprofen for 3 days
Trial: 16445331
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy and 35 minutes of CPM applications daily
Trial: 16445331
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy and 2 hours of CPM applications daily
Trial: 15540744
Drug: Transdermal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal laser stimulation of the posterior tibial nerve, performed daily for 30 seconds over the SP6 acupuncture point for 12 weeks
Trial: 11236073
Drug: Mirtazapine add
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine add on therapy to haloperidol 5 mg
Trial: 11236073
Drug: Placebo add
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add on therapy to haloperidol 5 mg
Trial: 9286889
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 microg/kg in 100 ml normal saline)
Trial: 8361794
Drug: High-iron content
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-iron content premature formula (15 mg/L)
Trial: 8361794
Drug: Low-iron content
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron content premature formula (3 mg/L)
Trial: 8361794
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk mixed with liquid fortifier (1.7 mg/L)
Trial: 3731212
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg loading dose on day 1, 4 mg/kg/day for 3 days)
Trial: 3731212
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aminophylline treatment)
Trial: 23656848
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg/d)